For many patients, GLP-1 drugs like Ozempic and Wegovy lead to substantial weight loss. But some see much less benefit, and researchers are trying to figure out why.
A new set of objective and simple phenotyping tests that categorize patients by four distinct subtypes of obesity is set to disrupt obesity care, by enabling the tailoring of therapy to a patient's syndrome to create care that is more successful and cost-effective.
Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.
